WESTBURY, N.Y., April 19 /PRNewswire/ -- Tishcon Corp. announced that the U.S. FDA has granted the firm Orphan Drug Designations for UBIQUINOL (Coenzyme Q10) in the treatment of
1- Pediatric Congestive Heart Failure, and
2- Huntington's Disease
Tishcon Corp. was also granted an Orphan Drug Designation for Coenzyme Q10 (Ubi-Q-Gel(R)) in the treatment of Mitochondrial Cytopathies, in 1999.
CONTACT: Raj Chopra, Chairman, CEO of Tishcon Corp., +1-516-333 3050,Raj@Tishcon.com